Pfizer: FDA greenlights generic version of Neulasta
(CercleFinance.com) - Pfizer announced on Thursday that the US FDA has approved its generic version of Neulasta, an Amgen drug aimed at reducing the frequency of infections in patients being treated for non-myeloid malignancies.
The US biopharmaceutical group said in a statement that it plans to market its biosimilar product in the US by the end of the year.
Yesterday, Pfizer reported "positive" Phase 3 results for its Janus kinase 1 (JAK1) inhibitor in the treatment of atopic dermatitis (eczema) in teenagers (12 to 18 years old).
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The US biopharmaceutical group said in a statement that it plans to market its biosimilar product in the US by the end of the year.
Yesterday, Pfizer reported "positive" Phase 3 results for its Janus kinase 1 (JAK1) inhibitor in the treatment of atopic dermatitis (eczema) in teenagers (12 to 18 years old).
Copyright (c) 2020 CercleFinance.com. All rights reserved.